Association of Biologic Therapy with Coronary Inflammation in Patients with Psoriasis as assessed by Perivascular Fat Attenuation Index
Chronic inflammatory diseases, including psoriasis, are associated with increased cardiovascular (CV) risk, which may be reduced when treating the underlying psoriasis.
This finding has opened interest to whether treating areas of low-grade inflammation in the body may be associated with downstream CV risk. A study of patients with moderate to severe psoriasis recently found that treatment of psoriasis with biologic therapy, including anti–tumor necrosis factor α (TNF-α), anti–interleukin (IL) 17, or anti–IL-12/23 therapy, may modulate coronary plaque compared with no biologic therapy.
Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers: A clinical consensus statement from the European Society of Cardiology Working Group on Coronary Pathophysiology and Micro-circulation
This clinical consensus statement from the European Society of Cardiology defines perivascular adipose tissue (PVAT) and highlights the biological mechanisms…
SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels
Abstract: Patients with coronavirus disease 2019 (COVID-19) present increased risk for ischemic cardiovascular complications up to 1 year after infection. Although…